As stated in section 21 CFR 312.300(a), Subpart I contains the requirements for the use of investigational new drugs and approved drugs where availability is limited by a risk evaluation and mitigation strategy (REMS) when the primary purpose is to diagnose,monitor, or treat a patient's disease or condition.